about
Open science is a research acceleratorResolution of praziquantelArtemisinin Antimalarials Do Not Inhibit Hemozoin FormationArtemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapsesImmunochromatography-based rapid diagnostic tests for diagnosing uncomplicated malaria in endemic countriesArtemisinin-based combination therapy for treating uncomplicated malariaDrugs for treating urinary schistosomiasisArtemisinin-based combination therapy for treating uncomplicated malariaPotential drug development candidates for human soil-transmitted helminthiasesBest practices for sharing information through data platforms: establishing the principlesDrug development for neglected diseases: a deficient market and a public-health policy failureCost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, IndiaPopulation pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patientsResidual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistanceCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentMore efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effectsShifts in Mycobacterial Populations and Emerging Drug-Resistance in West and Central AfricaEvaluating clinical trial designs for investigational treatments of Ebola virus diseaseExperimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical TrialOpen source drug discovery - a limited tutorialDengue Contingency Planning: From Research to Policy and PracticeThe need for operational research and capacity-building in support of the Global Technical Strategy for Malaria 2016-2030.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataComparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.The lipid moiety of haemozoin (Malaria Pigment) and P. falciparum parasitised red blood cells bind synthetic and native endothelin-1The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia.Malaria in adolescence: burden of disease, consequences, and opportunities for intervention.Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.In vivo parasitological measures of artemisinin susceptibilityMethodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004.Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibodyRandomised controlled trials for Ebola: practical and ethical issuesArtemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays.Assessing drivers of full adoption of test and treat policy for malaria in Senegal.First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.
P50
Q21004179-870B7EED-73AD-494C-8059-53FD886B5C96Q21144507-4D071D72-6AD7-4E37-AEB7-003C18F6E54AQ22061803-02214DB8-2DDA-4C90-908D-6CC7C45C0F44Q24236067-318C17E3-208D-46F3-B480-74C8809ABA5CQ24240783-78C36B74-0669-4F85-85CC-8330B6F5BE0CQ24241785-323FAFA8-E838-48B4-AE7A-EFCEBE8833A9Q24241883-C96A6196-C03E-448F-80A9-F43635D01B98Q24242461-95D03304-2E63-4C2F-8344-76BDDAD37B6BQ27306274-7605A2AF-4AF8-4142-A27D-E1A164B0321BQ27469125-21F4C6FB-8675-4B49-8688-DDA74FA6E1DEQ28207953-8C628602-0973-4E70-9964-89EBDE752344Q28250267-5D4F7122-ECAF-408F-BF6A-A27CEBAAD597Q28469076-E915AB18-DDA2-4C1C-94AF-5881C25DDE67Q28472222-39D14F84-BC72-4AC9-B875-6DE368BC3CACQ28475431-B8D1BC80-9903-4DAE-A7A7-296D86E8C524Q28483969-62329719-8FB6-408E-BE82-0C0D0271E625Q28542627-A7551632-1516-478D-B9F8-545F9179C0BBQ28546358-93FE1F1E-863D-4FFC-ADB6-F3A3990304C0Q28551448-B4B84F32-597B-4CE2-88A3-F16EB236DEDAQ28660808-499DE60E-108B-4C71-98DF-FF53B834BA52Q30151773-29C828FA-BE2F-4D4E-A13E-CD0CEA55D87EQ30384988-9A18FF78-B7E4-4827-B8DD-34C33307AF05Q30498213-61C7A74A-2082-4C5B-ABC1-677CCD7A5F4FQ30936416-C32F76C8-4EC9-4369-A496-D86BCCB440BBQ33399342-5A67286F-2112-4162-9951-05742D5AAB82Q33692573-544E9BED-C570-47DC-9C3E-CE6A03B19191Q34272998-59667348-ECD0-4EB2-AD2C-D436BFB68FDFQ34584180-282CB8D5-833B-4649-8292-592480BCB6A1Q34654206-F059FB9E-B054-40FB-9A24-64094E0C139AQ34768663-1DDE51B7-7E5E-48A2-BD81-3BCBDCF242C7Q34807496-FA2F9BA8-756B-4D7B-8A41-CEC989F72245Q34921155-5AEE1C30-C553-4CA2-814C-E1A07FC3F16AQ35127949-6E0916C2-087E-4EA6-BF3E-8ED05ABA2E78Q35245962-C17F0A80-E774-4FE3-9874-FF9C83A7D2B0Q35350529-9CD830D6-8144-46A0-80E6-302492A4315DQ35360159-9CC28916-AAFB-4DA3-80DE-C6B7F11C4A52Q35676996-E77C4EEE-DAE5-4D54-9AAB-224E8B568E5DQ35746141-1D486AB9-F5C0-48E5-A111-622B1A1DCBE0Q35836617-5F87F13F-D7ED-4E5B-BBF3-2F03D1A67626Q35856542-A2C36473-A123-4413-AAA5-AC7B25D6F1C5
P50
name
Piero Olliaro
@en
Piero Olliaro
@nl
type
label
Piero Olliaro
@en
Piero Olliaro
@nl
prefLabel
Piero Olliaro
@en
Piero Olliaro
@nl